S 646240
Alternative Names: S-646240Latest Information Update: 05 Nov 2023
At a glance
- Originator OncoTherapy Science; Shionogi
- Class Eye disorder therapies; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 02 Feb 2016 Discontinued - Phase-II for Age-related macular degeneration in Japan (SC)
- 23 Jul 2015 Phase-IIa is ongoing for Age-related macular degeneration in Japan
- 01 Dec 2014 Shionogi completes a phase II trial in Age-related macular degeneration in Japan (UMIN000008040)